Tower Research Capital (TRC)’s Evoke Pharma EVOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-40
| Closed | -$199 | – | 5269 |
|
|
2025
Q3 | $199 | Sell |
40
-1,948
| -98% | -$9.66K | ﹤0.01% | 5070 |
|
|
2025
Q2 | $5.17K | Buy |
1,988
+1,775
| +833% | +$5.11K | ﹤0.01% | 4220 |
|
|
2025
Q1 | $586 | Buy |
+213
| New | +$904 | ﹤0.01% | 4864 |
|
|
2024
Q4 | – | Sell |
-816
| Closed | -$3.88K | – | 5771 |
|
|
2024
Q3 | $3.88K | Buy |
816
+193
| +31% | +$1.02K | ﹤0.01% | 4746 |
|
|
2024
Q2 | $3.96K | Buy |
623
+6
| +1% | +$36 | ﹤0.01% | 4840 |
|
|
2024
Q1 | $4.52K | Buy |
617
+80
| +15% | +$680 | ﹤0.01% | 4668 |
|
|
2023
Q4 | $6.77K | Buy |
537
+54
| +11% | +$802 | ﹤0.01% | 4699 |
|
|
2023
Q3 | $7.99K | Buy |
483
+18
| +4% | +$295 | ﹤0.01% | 4411 |
|
|
2023
Q2 | $9.21K | Buy |
465
+133
| +40% | +$2.91K | ﹤0.01% | 4319 |
|
|
2023
Q1 | $8K | Buy |
332
+261
| +368% | +$10.2K | ﹤0.01% | 4623 |
|
|
2022
Q4 | $2K | Sell |
71
-116
| -62% | -$2.56K | ﹤0.01% | 5357 |
|
|
2022
Q3 | $4K | Sell |
187
-13
| -7% | -$427 | ﹤0.01% | 5246 |
|
|
2022
Q2 | $8K | Buy |
200
+125
| +167% | +$5.96K | ﹤0.01% | 4673 |
|
|
2022
Q1 | $5K | Buy |
75
+46
| +159% | +$3.67K | ﹤0.01% | 5043 |
|
|
2021
Q4 | $2K | Buy |
+29
| New | +$4.06K | ﹤0.01% | 5617 |
|
|
2021
Q1 | – | Sell |
-8
| Closed | -$3K | – | 5472 |
|
|
2020
Q4 | $3K | Sell |
8
-42
| -84% | -$21.6K | ﹤0.01% | 4792 |
|
|
2020
Q3 | $34K | Buy |
+50
| New | +$31.9K | ﹤0.01% | 3681 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$1K | – | 3842 |
|
|
2016
Q2 | $1K | Sell |
1
-6
| -86% | -$4.71K | ﹤0.01% | 4144 |
|
|
2016
Q1 | $5K | Sell |
7
-25
| -78% | -$12.8K | ﹤0.01% | 2675 |
|
|
2015
Q4 | $15K | Buy |
+32
| New | +$16.3K | ﹤0.01% | 1604 |
|
|
2015
Q3 | – | Sell |
-10
| Closed | -$7K | – | 4205 |
|
|
2015
Q2 | $7K | Buy |
10
+9
| +900% | +$7.66K | ﹤0.01% | 2988 |
|
|
2015
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 4049 |
|
|
2014
Q4 | $1K | Sell |
1
-2
| -67% | -$1.65K | ﹤0.01% | 3625 |
|
|
2014
Q3 | $3K | Buy |
3
+2
| +200% | +$1.93K | ﹤0.01% | 3598 |
|
|
2014
Q2 | $1K | Buy |
+1
| New | +$1.15K | ﹤0.01% | 3651 |
|
Tower Research Capital (TRC)'s EVOK Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of Evoke Pharma (EVOK) in Q4 2025, closing a stake of 40 shares — an estimated $199 sold.
Tower Research Capital (TRC) first reported a position in EVOK in Q2 2014 and held it in 25 quarters. The position peaked at $34K in Q3 2020. 0 funds tracked by Wall St. Rank hold EVOK as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining Evoke Pharma position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 40 Evoke Pharma shares in Q4 2025, an estimated $199.
- Tower Research Capital (TRC) first reported a position in Evoke Pharma in Q2 2014 and held it in 25 quarters.
- Tower Research Capital (TRC)'s Evoke Pharma position peaked at $34K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.